Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.

Molecular biotechnology - 1 Dec 2020

Nikooharf Abolfazl, Arezumand Roghaye, Mansouri Kamran, Khoshi Amir Hossein, Namdar Ahmadabad Hassan

Abstract excerpt

During the past two decades, tumor therapy based on monoclonal antibody has been found as a confident therapeutic approach in solid tumors and hematologic malignancies. Nanobodies are the smallest fragment of an antigen-binding domain in heavy chain-only antibody originated from the Camelidae family. Accordingly, they are being recently developed rapidly as diagnostic and therapeutic agents. In this regard,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody Affinity

Share to Cell Movement

Share to Human Umbilical Vein Endothelial Cells

Share to MCF-7 Cells

Share to Recombinant Proteins

Share to Single-Domain Antibodies

Source

Identifiers

PMID: 32975735
DOI: 10.1007/s12033-020-00275-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.PMID 32975735Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity Read ↗

Biology of vascular endothelial growth factorsSemantic proximity Read ↗

Study on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsSemantic proximity Read ↗

A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor ActivitySemantic proximity Read ↗

[Monoclonal antibodies in high-grade gliomas].Semantic proximity Read ↗

The Application of Nanobody in CAR-T TherapySemantic proximity Read ↗

Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapySemantic proximity Read ↗

Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)Semantic proximity Read ↗

Enhancing Anti-Angiogenic Therapy with Bevacizumab-Loaded Nanoflowers Through The Chorioallantoic Membrane AssaySemantic proximity Read ↗

Small p53 derived peptide suitable for robust nanobodies dimerization.Semantic proximity Read ↗

Study on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsStudy on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.